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BACKGROUND
Severe anemia (hemoglobin level, <6 g per deciliter) is a leading cause of hospital ad-
mission and death in children in sub-Saharan Africa. The World Health Organization 
recommends transfusion of 20 ml of whole-blood equivalent per kilogram of body 
weight for anemia, regardless of hemoglobin level.
METHODS
In this factorial, open-label trial, we randomly assigned Ugandan and Malawian children 
2 months to 12 years of age with a hemoglobin level of less than 6 g per deciliter and 
severity features (e.g., respiratory distress or reduced consciousness) to receive immedi-
ate blood transfusion with 20 ml per kilogram or 30 ml per kilogram. Three other 
randomized analyses investigated immediate as compared with no immediate transfu-
sion, the administration of postdischarge micronutrients, and postdischarge prophy-
laxis with trimethoprim–sulfamethoxazole. The primary outcome was 28-day mortality.
RESULTS
A total of 3196 eligible children (median age, 37 months; 2050 [64.1%] with malaria) were 
assigned to receive a transfusion of 30 ml per kilogram (1598 children) or 20 ml per kilo-
gram (1598 children) and were followed for 180 days. A total of 1592 children (99.6%) in 
the higher-volume group and 1596 (99.9%) in the lower-volume group started transfusion 
(median, 1.2 hours after randomization). The mean (±SD) volume of total blood transfused 
per child was 475±385 ml and 353±348 ml, respectively; 197 children (12.3%) and 300 
children (18.8%) in the respective groups received additional transfusions. Overall, 55 
children (3.4%) in the higher-volume group and 72 (4.5%) in the lower-volume group died 
before 28 days (hazard ratio, 0.76; 95% confidence interval [CI], 0.54 to 1.08; P = 0.12 by 
log-rank test). This finding masked significant heterogeneity in 28-day mortality accord-
ing to the presence or absence of fever (>37.5°C) at screening (P=0.001 after Sidak correc-
tion). Among the 1943 children (60.8%) without fever, mortality was lower with a transfu-
sion volume of 30 ml per kilogram than with a volume of 20 ml per kilogram (hazard 
ratio, 0.43; 95% CI, 0.27 to 0.69). Among the 1253 children (39.2%) with fever, mortality 
was higher with 30 ml per kilogram than with 20 ml per kilogram (hazard ratio, 1.91; 
95% CI, 1.04 to 3.49). There was no evidence of differences between the randomized 
groups in readmissions, serious adverse events, or hemoglobin recovery at 180 days.
CONCLUSIONS
Overall mortality did not differ between the two transfusion strategies. (Funded by the 
Medical Research Council and Department for International Development, United 
Kingdom; TRACT Current Controlled Trials number, ISRCTN84086586.)
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S
evere anemia (hemoglobin level, <6 g 
per deciliter) is a leading cause of hospital-
ization and death in children in sub-Saharan 
Africa.1-4 The demand for blood transfusion is 
high, with most transfusions administered to 
young children and women.5,6 However, blood 
donation in most African countries is scarcely 
adequate; most countries collect fewer than 5 units 
per 1000 population.7 World Health Organiza-
tion (WHO) guidelines, therefore, encourage 
rational blood use, recommending (on the basis 
of expert opinion) transfusion only for children 
with profound anemia (hemoglobin level, <4 g 
per deciliter) or life-threatening severe anemia 
(4 to 6 g per deciliter) and a uniform transfusion 
volume of 20 ml of whole blood or its equivalent 
per kilogram of body weight,8 irrespective of 
hemoglobin level. Outcomes remain unsatisfac-
tory, with high reported in-hospital mortality (9 to 
10%)2,3 and 6-month mortality (12%).4
If standard formulae for transfusion volume9,10 
are applied, the one-size-fits-all recommendation 
of 20 ml per kilogram appears to underestimate 
transfusion requirements by approximately 
30%.11,12 A consensus guideline on transfusion 
in critically ill children noted a weak global evi-
dence base and specifically highlighted a need to 
evaluate transfusion volumes and clinical out-
comes.13 In addition to providing superior cor-
rection of anemia, higher transfusion volumes 
may reduce the need for second transfusions,11,12 
thus saving resources and decreasing the risks 
associated with receiving blood from multiple 
donors.
The Transfusion and Treatment of Severe 
Anemia in African Children Trial (TRACT) in-
vestigated four interventions in African children 
with hemoglobin levels of less than 6 g per 
deciliter.14 Here, we report the results comparing 
the transfusion of 20 ml of whole-blood equiva-
lent per kilogram with the transfusion of 30 ml 
per kilogram; a companion article from the trial 
about immediate as compared with no immedi-
ate transfusion also appears in this issue of the 
Journal.15
Me thods
Trial Design and Oversight
We conducted an open-label, multicenter, factorial, 
randomized trial at three hospitals in Uganda 
and one in Malawi. Children 2 months to 12 
years of age who had been admitted with severe 
anemia (hemoglobin level, <6 g per deciliter) 
were eligible to participate. Children who had 
known chronic disease (kidney or liver failure, 
malignant conditions, heart failure, or congeni-
tal heart disease) or who had been admitted for 
burns, trauma, or surgery were excluded, as were 
children who had already received a transfusion 
during the primary hospitalization and infants 
who had been exclusively breast-fed.14 (For de-
tails, see the Methods section in the Supple-
mentary Appendix, available with the full text 
of this article at NEJM.org.)
In the first stratum, children with compli-
cated severe anemia (a hemoglobin level <4 g per 
deciliter, reduced consciousness, respiratory dis-
tress, acute hemoglobinuria,16 disclosed sickle 
cell disease, or a combination of these severity 
features) were randomly assigned in a 1:1 ratio to 
receive 30 ml of whole blood per kilogram (15 ml 
of packed or settled cells per kilogram) or 20 ml 
of whole blood per kilogram (10 ml of packed or 
settled cells per kilogram). In the second stra-
tum, children with uncomplicated severe anemia 
(4 to 6 g per deciliter without signs of severity) 
were randomly assigned in a 1:1 ratio to imme-
diate transfusion of whole-blood equivalent or 
no immediate transfusion (until or unless sever-
ity criteria were met). The patients in the imme-
diate-transfusion group were then assigned, with 
the use of a factorial design, to receive either 30 ml 
per kilogram or 20 ml per kilogram.15 The groups 
that were assigned to immediate or no immedi-
ate transfusion are reported separately.15 Here, 
we do not report the results of randomized 
analyses of 3 months of postdischarge adjunc-
tive micronutrient supplementation or prophy-
laxis with trimethoprim–sulfamethoxazole.
Ethics committees at Imperial College Lon-
don, Makerere University (Kampala, Uganda), 
and the College of Medicine (Blantyre, Malawi) 
approved the protocol, which is available at 
NEJM.org. The authors vouch for the complete-
ness and accuracy of the data and for the fidel-
ity of the trial to the protocol; all the authors 
contributed to the writing of the manuscript. 
There was no commercial support for the trial.
Screening and Randomization
Children with suspected severe anemia (severe 
pallor17) had hemoglobin measured (with the 
use of a HemoCue18 system) and were clinically 
assessed for severity. Either oral assent with de-
layed written informed consent19 or written in-
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formed consent from the children’s parents or 
guardians was obtained before randomization, 
which was stratified according to center and 
severity stratum. Details are provided in the ac-
companying article by Maitland et al.15 and in 
the Methods section in the Supplementary Ap-
pendix.
Trial Procedures
General clinical management, timing of obser-
vation, and blinding are described in Maitland 
et al.15 Units of blood were weighed before and 
after transfusion and administered in burettes 
with volume markers to ensure an accurate vol-
ume.20 Whole-blood cells were transfused over a 
period of 3 to 4 hours, and packed or settled cells 
were transfused over a period of 2 to 3 hours. 
Blood was not specifically reserved for the trial; 
enrollment was temporarily suspended if blood 
became unavailable. Additional transfusions were 
permitted for new or persistent hemoglobin levels 
of less than 4 g per deciliter or severity features 
(see above) if the hemoglobin level remained 
below 6 g per deciliter. Second transfusions fol-
lowed the initial randomized volume; children 
who continued to fulfill the trial criteria received 
further transfusions of 20 ml of whole-blood 
equivalent per kilogram.
Outcomes
The primary outcome was mortality at 28 days 
after randomization. Secondary outcomes were 
mortality at 48 hours, 90 days, and 180 days; the 
development of new profound anemia (hemoglo-
bin level, <4 g per deciliter) during the primary 
hospitalization or development of severe anemia 
(<6 g per deciliter) after discharge; hospital re-
admission; the percentage of patients with ane-
mia correction (>9 g per deciliter, on the basis of 
WHO guidelines); suspected transfusion reac-
tions (febrile reactions and transfusion-related 
acute lung injury); serious adverse events; and 
cost and cost-effectiveness. Details are provided 
in the article by Mait land et al.15
Statistical Analysis
We determined that the randomization of 2977 
children would provide the trial with 80% power 
to detect a 30% relative difference in 28-day mor-
tality (13.7% in the group receiving 20 ml per 
kilogram and 9.6% in the group receiving 30 ml 
per kilogram), assuming that 6% of the children 
would be lost to follow-up by 6 months (allow-
ing for different primary-outcome timing in 
other randomizations) and a two-sided alpha 
level of 0.013 (four comparisons across random-
izations). (For details, see the Methods section 
in the Supplementary Appendix.) Randomized 
groups were compared on an intention-to-treat 
basis with the use of log-rank tests or competing-
risks methods for time-to-event outcomes, Fisher’s 
exact test for binary outcomes, and generalized 
estimating equations for repeated measures. Con-
fidence intervals and P values were not adjusted 
for multiple testing, except for unadjusted hetero-
geneity P values of less than 0.05 for subgroup 
analyses, which are reported as Sidak-adjusted 
values; 16 subgroup analyses were performed. 
For details regarding meetings of the data moni-
toring committee and further details of the statis-
tical analysis, see Maitland et al.15 and the Meth-
ods section in the Supplementary Appendix.
R esult s
Participating Children
From September 2014 through May 2017, a total 
of 3199 children with hemoglobin levels of less 
than 6 g per deciliter were randomly assigned to 
receive 30 ml of whole-blood equivalent per kilo-
gram or 20 ml of whole-blood equivalent per 
kilogram; consent was declined for 3 children 
after oral assent had been obtained, and they 
were excluded (Fig. 1). Of the 3196 included 
children, 2418 (75.7%) had a hemoglobin level of 
less than 4 g per deciliter or severity features; 
1137 (35.6%) had two or more severity features. 
Baseline characteristics were balanced between 
the randomized groups (Table 1, and Table S1 in 
Figure 1 (facing page). Screening, Randomization,  
and Follow-up.
Severity features of anemia were a hemoglobin level of 
less than 4 g per deciliter, reduced consciousness, re-
spiratory distress, acute hemoglobinuria, or disclosed 
sickle cell disease. Data regarding loss to follow-up are 
presented for 0 to 28 days and 0 to 180 days (i.e., data 
that were lost by 28 days are a subset of the data lost 
by 180 days). No screening took place on days when 
no blood was available for transfusion.
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3199 Underwent randomization
6171 Children were assessed for eligibility
787 Were assigned to control and were
not part of this comparison
2185 Were excluded
1415 Did not have anemia
329 Had parent or guardian who was unable
or unwilling to give consent
102 Had parent or guardian who was unable
to commit to follow-up
93 Did not have blood sample available
54 Were not in age range
50 Had terminal illness or renal, liver,
or heart failure
34 Were breast-feeding
31 Had a severity feature, but enrollment
to this part of the trial had closed
19 Were admitted for surgery
5 Died during eligibility screening
53 Had unknown reason
1598 Were assigned to transfusion of 30 ml
of whole-blood equivalent/kg of body weight
1601 Were assigned to transfusion of 20 ml
of whole-blood equivalent/kg of body weight
3 Had parent or guardian who
declined consent after oral assent
1598 Were included in the analysis 1598 Were included in the analysis
1592 Received transfusion
5 Died before start of transfusion
1 Had health form that was lost
13 Were lost to follow-up by 28 days
1 Was withdrawn
5 Left center during primary hospitalization
1 Had parent or guardian who lost
interest in trial
6 Could not be traced
65 Were lost to follow-up by 180 days
4 Were withdrawn
5 Left center during primary hospitalization
4 Had parent or guardian who lost
interest in trial
2 Had parent or guardian who became
unable to bring child to the center
because of social problems
7 Moved away
43 Could not be traced
1596 Received transfusion
2 Died before start of transfusion
12 Were lost to follow-up by 28 days
3 Were withdrawn
2 Left center during primary hospitalization
1 Moved away
6 Could not be traced
65 Were lost to follow-up by 180 days
4 Were withdrawn
2 Left center during primary hospitalization
3 Had parent or guardian who lost
interest in trial
9 Moved away
47 Could not be traced
1598 Eligible children underwent
randomization
1598 Eligible children underwent
randomization
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Characteristic
Lower Volume: 
20 ml/kg 
(N = 1598)
Higher Volume: 
30 ml/kg 
(N = 1598)
Total 
(N = 3196)
Median age (IQR) — mo 37 (18–64) 37 (18–63) 37 (18–64)
Male sex — no. (%) 913 (57.1) 900 (56.3) 1813 (56.7)
Median hemoglobin (IQR) — g/dl 4.3 (3.4–5.2) 4.2 (3.3–5.2) 4.2 (3.4–5.2)
Median weight (IQR) — kg 12 (9–16) 12 (9.2–15.8) 12 (9.1–16.0)
Median heart rate (IQR) — beats/min 147 (131–162) 146 (131–161) 146 (131–161)
Median circumference of mid upper arm (IQR) — cm 14.5 (13.5–15.5) 14.5 (13.5–15.5) 14.5 (13.5–15.5)
History of fever in current illness — no. (%) 1540 (96.4) 1566 (98.0) 3106 (97.2)
Median axillary temperature at screening (IQR) — °C† 37.3 (36.7–38.0) 37.3 (36.7–38.0) 37.3 (36.7–38.0)
Fever — no. (%) 618 (38.7) 635 (39.7) 1253 (39.2)
Hypothermia — no. (%) 67 (4.2) 55 (3.4) 122 (3.8)
Median blood pressure (IQR) — mm Hg
Systolic 91 (84–98) 92 (83–99) 91 (83–99)
Diastolic 54 (47–61) 54 (47–62) 54 (47–62)
Median oxygen saturation (IQR) — % 97 (95–99) 97 (95–99) 97 (95–99)
Median respiratory rate (IQR) — breaths/min 42 (33–51) 41 (34–52) 41 (34–52)
Shock — no. (%)‡ 527 (33.0) 531 (33.2) 1058 (33.1)
Severe dehydration — no. (%)§ 120 (7.5) 120 (7.5) 240 (7.5)
HIV positivity — no./total no. (%) 49/1526 (3.2) 49/1520 (3.2) 98/3046 (3.2)
Malaria slide or RDT positivity — no. (%) 1025 (64.1) 1025 (64.1) 2050 (64.1)
Positive blood culture — no./total no. (%) 54/1374 (3.9) 38/1377 (2.8) 92/2751 (3.3)
Median C-reactive protein (IQR) — mg/dl 61.2 (23.3–112.3) 62.4 (24.1–119.5) 61.6 (23.8–114.4)
Median lactate (IQR) — mmol/liter 3.0 (2–4.7) 2.8 (1.9–4.6) 2.9 (1.9–4.7)
Previous blood transfusion in current illness — no. (%) 32 (2.0) 32 (2.0) 64 (2.0)
Blood transfusion ever — no./total no. (%) 586/1583 (37.0) 573/1590 (36.0) 1159/3173 (36.5)
Severity features — no. (%)¶
Any 1208 (75.6) 1210 (75.7) 2418 (75.7)
Impaired consciousness 373 (23.3) 385 (24.1) 758 (23.7)
Respiratory distress 436 (27.3) 424 (26.5) 860 (26.9)
Hemoglobinuria 300 (18.8) 290 (18.1) 590 (18.5)
Profound anemia 660 (41.3) 682 (42.7) 1342 (42.0)
Reported sickle cell disease 237 (14.8) 226 (14.1) 463 (14.5)
Sickle cell disease ascertained by genotyping — no./ 
total no. (%)‖
440/1579 (27.9) 446/1588 (28.1) 886/3167 (28.0)
*  There was no evidence of imbalances in baseline characteristics between the randomized groups (P≥0.06). HIV denotes 
human immunodeficiency virus, IQR interquartile range, and RDT rapid diagnostic test.
†  Axillary temperature was measured with a digital thermometer. Fever was defined as a temperature of more than 37.5°C. 
Hypothermia was defined as a temperature of less than 36.0°C.
‡  Shock was defined by any of the following: a capillary refill time of more than 2 seconds, temperature gradient, or weak 
pulse.
§  Severe dehydration was defined as decreased skin turgor, sunken eyes, or both.
¶  Profound anemia was defined as a hemoglobin level of less than 4 g per deciliter. Reported sickle cell disease was de-
fined according to a parental statement at screening.
‖  Sickle cell disease was ascertained by the presence of hemoglobin SS in batch genotyping at Kilifi, Kenya. For detailed 
results, see Table S1 in the Supplementary Appendix.
Table 1. Characteristics of the Children at Baseline.*
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the Supplementary Appendix). The median age 
was 37 months (interquartile range, 18 to 64). 
A history of fever was very common (3106 of 
3196 children [97.2%]), and a documented tem-
perature of more than 37.5°C (1253 of 3196 
[39.2%]) and shock (1058 of 3196 [33.1%]) at 
screening were common. Plasmodium falciparum 
malaria was present in 2050 children (64.1%), 
but human immunodeficiency virus (HIV) in-
fection, culture-proven bacteremia, and severe 
malnutrition were found in less than 4% of the 
children. The number of children with sickle cell 
disease increased from 463 (14.5%) (reported) to 
886 (27.7%) (actual) after batch genotyping.
Randomized Interventions
A total of 1592 children (99.6%) who were as-
signed to receive 30 ml per kilogram and 1596 
(99.9%) who were assigned to 20 ml per kilo-
gram started transfusion, both at a median of 
1.2 hours (interquartile range, 0.9 to 1.7) after 
randomization. First transfusions were within 
3 ml per kilogram of the randomized volume in 
1525 of 1592 children (95.8%) in the higher-
volume group and in 1551 of 1596 (97.2%) in the 
lower-volume group and were infused over a 
median of 2.9 hours (interquartile range, 2.1 to 
4.0) and 2.6 hours (interquartile range, 2.1 to 3.9), 
respectively. First transfusions were stopped for 
reactions in 17 of 1592 children (1.1%) in the 
higher-volume group and in 10 of 1596 (0.6%) in 
the lower-volume group. First transfusions were 
whole blood in 700 of 1592 children (44.0%) in 
the higher-volume group and in 703 of 1596 
(44.0%) in the lower-volume group; the median 
hemoglobin level of the donor unit was 16.4 g 
per deciliter (interquartile range, 13.8 to 19.2), 
and the median blood storage time was 12 days 
(interquartile range, 6 to 19) (Table S2 and Fig. S1 
in the Supplementary Appendix).
A further transfusion or transfusions occurred 
in 197 of 1592 children (12.4%) in the higher-
volume group and in 300 of 1596 (18.8%) in the 
lower-volume group (absolute difference, 6.4 per-
centage points; 95% confidence interval [CI], 3.9 
to 8.9) (Fig. S2 in the Supplementary Appendix); 
the randomized volume strategy was followed in 
1841 of 1914 transfusions (96.2%) in the higher-
volume group and in 2024 of 2074 (97.6%) in the 
lower-volume group. During the primary hospi-
talization, the mean (±SD) volume of whole-blood 
equivalent was 475±385 ml in the higher-volume 
group and 353±348 ml in the lower-volume 
group. Overall, similar numbers of units of blood 
were used (mean units, 1.47±1.03 in the higher-
volume group and 1.46±1.12 in the lower-volume 
group) (Table S3 in the Supplementary Appendix).
Hemoglobin Recovery
The hemoglobin level increased more at 48 hours 
among children receiving 30 ml per kilogram 
than among those receiving 20 ml per kilogram 
(mean difference, 0.99 g per deciliter; 95% CI, 
0.80 to 1.18) (Fig. S3A in the Supplementary Ap-
pendix). Similarly, hemoglobin recovery to more 
than 9 g per deciliter occurred faster with 30 ml 
per kilogram, and a new hemoglobin level of less 
than 4 g per deciliter occurred less frequently 
(Table 2, and Fig. S3B through S3E in the Sup-
plementary Appendix). However, from day 28 
through day 180, there was no evidence of dif-
ferences in hemoglobin level between the two 
groups (Fig. S3A and S3B in the Supplementary 
Appendix).
Mortality
Vital status at day 28 (primary outcome) was 
unknown for 13 children (0.8%) assigned to re-
ceive 30 ml per kilogram and 12 (0.8%) assigned 
to receive 20 ml per kilogram and at day 180 for 
65 children (4.1%) in each group. There was no 
evidence of differences in mortality between the 
two groups at day 28 — at which time 55 chil-
dren (3.4%) in the higher-volume group and 72 
(4.5%) in the lower-volume group had died (haz-
ard ratio, 0.76; 95% CI, 0.54 to 1.08; P = 0.12 by 
log-rank test) (Fig. 2A) — or at day 180 (Table 2). 
There was no evidence of interaction with other 
factorial randomizations to postdischarge micro-
nutrients (unadjusted P = 0.73) or trimethoprim–
sulfamethoxazole (P = 0.12) or with severity strata 
(P = 0.09). No cause could be assigned in 145 of 
288 deaths, primarily because these deaths oc-
curred outside the hospital or insufficient infor-
mation was available (Table S4 in the Supple-
mentary Appendix). Specific infections were the 
most commonly assigned primary cause of death 
(in 51 children [17.7%]), followed by hemato-
logic conditions (in 45 [15.6%]) and pneumonia 
(in 22 [7.6%]).
Of the 10 subgroup analyses that were pre-
specified in the protocol and 6 additional analy-
ses that were prespecified in the statistical 
analysis plan (available with the protocol at 
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Outcome
Higher Volume: 
30 ml/kg 
(N = 1598)
Lower Volume: 
20 ml/kg 
(N = 1598)
Total 
(N = 3196)
Hazard Ratio 
(95% CI)† P Value
Death — no. (%)
At 48 hr‡ 32 (2.0) 34 (2.1) 66 (2.1) 0.94 (0.58–1.52)
At 28 days: primary outcome 55 (3.4) 72 (4.5) 127 (4.0) 0.76 (0.54–1.08) 0.12
At 90 days‡ 93 (5.8) 114 (7.1) 207 (6.5) 0.81 (0.61–1.06)
At 180 days‡ 134 (8.4) 154 (9.6) 288 (9.0) 0.86 (0.68–1.08)
Correction of anemia during the primary hospitalization 
— no. (%)‡
678 (42.4) 349 (21.8) 1027 (32.1) 2.13 (1.89–2.41)§
Development of new profound anemia during the primary 
hospitalization — no. (%)‡
40 (2.5) 85 (5.3) 125 (3.9) 0.47 (0.32–0.68)§
Development of severe anemia after discharge  
— no. (%)‡
338 (21.2) 303 (19.0) 641 (20.1) 1.10 (0.94–1.28)§
Readmission to hospital — no. (%)‡ 301 (18.8) 278 (17.4) 579 (18.1) 1.08 (0.92–1.27)§
Serious adverse event
At least one event — no. of patients (%)‡ 431 (27.0) 416 (26.0) 847 (26.5) 1.03 (0.90–1.18) 0.63
No. of events 608 544 1152
Type of serious adverse event
Anemia¶
At least one event — no. of patients (%) 230 (14.4) 224 (14.0) 454 (14.2) 0.80‖
No. of events 323 292 615
Malaria
At least one event — no. of patients (%) 129 (8.1) 108 (6.8) 237 (7.4) 0.18‖
No. of events 149 119 268
Sepsis
At least one event — no. of patients (%) 67 (4.2) 78 (4.9) 145 (4.5) 0.40‖
No. of events 85 95 180
Hemoglobinuria
At least one event — no. of patients (%) 52 (3.3) 44 (2.8) 96 (3.0) 0.39‖
No. of events 64 51 115
Suspected allergic reaction — no. (%)‡** 25 (1.6) 20 (1.3) 45 (1.4) 0.55‖
Suspected transfusion-related lung injury — no. (%)‡** 2 (0.1) 3 (0.2) 5 (0.2) 1.00‖
Suspected raised intracranial pressure — no. (%)** 1 (0.1) 0 1 (<0.1)
*  Correction of anemia was defined as a hemoglobin level of more than 9 g per deciliter. Profound anemia was defined as a hemoglobin level 
of less than 4 g per deciliter. Severe anemia was defined as a hemoglobin level of less than 6 g per deciliter. Suspected transfusion-related 
lung injury refers to suspected pulmonary overload, transfusion-related acute lung injury, or transfusion-related cardiac overload. CI denotes 
confidence interval.
†  Hazard ratios are for the higher-volume group as compared with the lower-volume group. Confidence intervals have not been adjusted for 
multiple testing, and inferences drawn from the intervals may not be reproducible.
‡  This is a secondary outcome that was prespecified in the protocol. The P value is not reported except for adverse events.
§  This hazard ratio was estimated from competing-risks subhazard regression.
¶  The diagnosis of the serious adverse event of anemia (including anemia-related death) was made by the attending clinician (during the 
primary hospitalization and after discharge). There was no formal hemoglobin threshold required.
‖  This P value was calculated with Fisher’s exact test.
**  Grades of adverse events are shown in Table S9 in the Supplementary Appendix.
Table 2. Primary, Secondary, and Other Outcomes.*
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Figure 2. Mortality through 180 Days and at 28 Days.
The lower-volume group was assigned to receive 20 ml of whole-blood equivalent per kilogram, and the higher-volume group was assigned to receive 30 ml of whole-blood equiva-
lent per kilogram. The window for the 180-day visit was defined as 120 to 240 days after randomization.
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NEJM.org), one (fever [>35°C] vs. no fever at 
screening, prespecified in the protocol) showed 
substantial heterogeneity with respect to 28-day 
mortality (Sidak-adjusted P = 0.001; unadjusted 
P>0.08 for other comparisons) (Fig. 2B, and 
Figs. S4 and S5 in the Supplementary Appendix). 
In 1943 children (60.8%) with a body tempera-
ture of 37.5°C or less at screening, 24 of 963 
(2.5%) in the higher-volume group and 56 of 980 
(5.7%) in the lower-volume group died by 28 days 
(hazard ratio, 0.43; 95% CI, 0.27 to 0.69). In con-
trast, in 1253 children (39.2%) with fever at 
screening, 31 of 635 (4.9%) in the higher-volume 
group and 16 of 618 (2.6%) in the lower-volume 
group died by 28 days (hazard ratio, 1.91; 95% 
CI, 1.04 to 3.49).
With respect to the actual temperature at 
screening (rather than the prespecified dichoto-
mization at 37.5°C), the risk of death was high 
in both groups at very low and very high tempera-
tures (Fig. 2C). However, in the higher-volume 
group, the risk of death dropped more quickly as 
the temperature increased to 37.5°C before rising 
substantially, which led to almost equal and op-
posite benefits and risks from the two strate-
gies, depending on the temperature being above 
or no more than 37.5°C (Fig. 2D). As expected, 
there were some modest differences between 
children with fever and those without fever at 
screening in baseline characteristics (Table S5 in 
the Supplementary Appendix), but the receipt of 
other interventions was similar (Table S6 in the 
Supplementary Appendix). There was no evidence 
of heterogeneity in five additional exploratory sub-
group analyses (unadjusted P>0.2 for all com-
parisons) (Fig. S6 in the Supplementary Appen-
dix), nor was there heterogeneity according to 
the temperature 30 minutes after transfusion, 
when other treatments (including antipyretics) 
had also been initiated (unadjusted P = 0.10). 
When temperature at screening and 30 minutes 
after transfusion were considered, higher tem-
peratures at screening drove different treatment 
effects (Table S7 in the Supplementary Appen-
dix). Heterogeneity according to the presence or 
absence of fever persisted even after adjustment 
for a weak interaction with C-reactive protein 
levels (see the Results section in the Supplemen-
tary Appendix).
Heterogeneity according to the presence or 
absence of fever was already evident in mortality 
at 48 hours (Sidak-adjusted P = 0.05) and persisted 
through day 180 (Sidak-adjusted P = 0.06), with 
no strong evidence implicating any specific cause 
(Fig. S7 in the Supplementary Appendix). Tempera-
tures differed substantially between children with 
fever and those without fever at screening for 
8 hours after randomization (Fig. S8 in the Sup-
plementary Appendix). Recovery of hemoglobin 
level, heart rate, and respiratory rate occurred 
similarly in children with fever and those without 
fever (Fig. S9 in the Supplementary Appendix).
Secondary Clinical Outcomes to 180 Days
Children spent a median of 4 days (interquartile 
range, 3 to 5) in the hospital in the two groups, 
but the time until discharge was shorter in the 
group receiving 30 ml per kilogram than in the 
group receiving 20 ml per kilogram (hazard ratio, 
1.12; 95% CI, 1.04 to 1.20) (Fig. S10 in the 
Supplementary Appendix), with a mean length 
of stay of 4.7 days in the higher-volume group 
and 4.9 days in the lower-volume group. Readmis-
sion within 180 days occurred in 301 children 
(18.8%) in the higher-volume group and in 278 
(17.4%) in the lower-volume group (hazard ratio, 
1.08; 95% CI, 0.92 to 1.27) (Fig. S11 in the 
Supplementary Appendix), with no evidence of 
heterogeneity according to the presence or ab-
sence of fever at screening (unadjusted P = 0.78) 
(Fig. S7 in the Supplementary Appendix).
One or more serious adverse events occurred 
in 431 children (27.0%) in the higher-volume 
group and in 416 (26.0%) in the lower-volume 
group (P = 0.63) (Table 2, and Table S8 in the 
Supplementary Appendix), with no evidence of 
differences between the two groups in serious 
adverse events related to anemia, malaria, sepsis, 
or hemoglobinuria (P>0.15 for all comparisons). 
Allergic reactions occurred in 25 children (1.6%) 
in the higher-volume group and in 20 (1.3%) in 
the lower-volume group (P = 0.55); there were no 
fatal reactions (Table S9 in the Supplementary 
Appendix). Suspected pulmonary or cardiovas-
cular serious adverse events occurred in 2 children 
(0.1%) in the higher-volume group and in 3 (0.2%) 
in the lower-volume group (P = 1.00); there were 
2 deaths from pulmonary or cardiovascular causes. 
A neurologic (grade 3) serious adverse event oc-
curred in 1 child in the higher-volume group.
Costs and Cost-Effectiveness
The main cost drivers were hospital length of 
stay (mean, $33.38 [U.S. dollars] in children re-
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ceiving 30 ml per kilogram and $32.59 in chil-
dren receiving 20 ml per kilogram), blood trans-
fusions (mean, $25.18 and $27.26, respectively), 
and hemoglobin tests (mean, $8.53 and $8.46, 
respectively), resulting in total costs per child of 
$80.62 in the higher-volume group and $81.97 in 
the lower-volume group (Tables S10 through S12 
in the Supplementary Appendix). Life-years gained 
over a period of 180 days were slightly higher in 
the group receiving 30 ml (0.473) than in the 
group receiving 20 ml per kilogram (0.466). 
Overall, a transfusion volume of 30 ml per kilo-
gram appeared to offer additional benefits, at an 
increased cost of $87 per life-year gained through 
180 days (adjusted model) (Table S13 in the Sup-
plementary Appendix). However, for the subgroup 
without fever at screening, costs per life-year 
gained were reduced to $20 per life-year gained, 
whereas for the subgroup with fever at screen-
ing, a transfusion volume of 30 ml per kilogram 
was less costly but also less effective than a vol-
ume of 20 ml per kilogram. (Results of regression 
and sensitivity analyses are provided in the Re-
sults section in the Supplementary Appendix.)
28-Day Mortality
Key predictors of death by 28 days were clinical 
severity features, including the Blantyre coma 
score and convulsions (Table 3). A lower oxygen 
saturation, a higher respiratory rate, and a higher 
lactate level were also associated with increased 
mortality. Malaria infection reduced the risk of 
death, whereas HIV infection and AB blood 
group increased the risk. There was no evidence 
of association between 28-day mortality and the 
characteristics of the blood used (the hemoglo-
bin level of the donor unit, the type of blood unit 
transfused [hazard ratio for whole blood vs. 
packed or settled cells, 1.18; 95% CI, 0.78 to 
1.78], or the duration of storage) or the presence 
of sickle cell disease. Results were broadly simi-
lar at 180 days (see the Results section and Table 
S14 in the Supplementary Appendix).
Discussion
In this large, multicenter trial involving children 
with severe anemia, we observed no overall evi-
dence of differences in mortality at 48 hours, 28 
days, or 180 days between those receiving a 
transfusion volume approximately one third high-
er than recommended (30 ml per kilogram) and 
those receiving the recommended volume (20 ml 
per kilogram). By 48 hours, the higher-volume 
group had superior correction of anemia (to >9 g 
per deciliter), less development or redevelopment 
of profound anemia, and fewer additional trans-
fusions. Nevertheless, by day 28, hemoglobin 
levels were similar in the two groups, and the 
two strategies used similar numbers of units of 
blood per child overall.
The overall results obscure an important and 
potentially unusually strong interaction with 
fever, which meets six of nine relevant criteria 
proposed to assess credibility of subgroup find-
ings.21 Among the majority of children who did 
not have fever at admission, 28-day mortality 
with a transfusion volume of 30 ml per kilogram 
was less than half that with a transfusion volume 
Factor at Randomization
Hazard Ratio (95% CI) from 
Multivariable Model*
Malaria 0.52 (0.34–0.78)
Higher oxygen saturation 0.91 (0.88–0.94)†
Higher respiratory rate 1.03 (1.01–1.04)‡
Higher lactate level 1.09 (1.04–1.15)§
HIV positivity 2.58 (1.32–5.05)
Convulsions in current illness 1.87 (1.05–3.33)
Blantyre coma score¶
5 1.00
4 0.83 (0.31–2.17)
3 2.19 (0.97–4.95)
2 2.48 (1.22–5.05)
1 3.29 (0.97–12.5)
0 3.21 (1.04–9.89)
Blood type
O 1.00
A 1.03 (0.64–1.68)
B 0.74 (0.43–1.27)
AB 2.59 (1.41–4.78)
*  Estimates were adjusted for randomized comparison, continuous variation in 
temperature, and the interaction between the two with the use of natural cubic 
splines (details in the Supplementary Appendix).
†  Shown is the hazard ratio for each increment of 1% in oxygen saturation.
‡  Shown is the hazard ratio for each increment of 1 breath per minute in the 
 respiratory rate.
§  Shown is the hazard ratio for each increment of 1 mmol per liter in the lactate 
level.
¶  The Blantyre coma scale is used to assess malarial coma in children. Scores 
range from 0 to 5, with lower scores indicating lower levels of consciousness.
Table 3. Predictors of Death at 28 Days after Blood Transfusion in Children 
with a Hemoglobin Level of Less Than 6 g per Deciliter.
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of 20 ml per kilogram, a finding consistent with 
the hypothesis of the trial. This difference oc-
curred soon after randomization and persisted, 
at a cost of $20 per life-year gained, falling well 
within recently published cost-effectiveness 
thresholds for Uganda and Malawi.22 Because 6 to 
15% of children who are admitted to African 
hospitals have severe anemia,2,3 a transfusion 
strategy of 30 ml per kilogram may have sub-
stantial implications for improving outcome for 
the two thirds who are hospitalized with anemia 
but without documented fever.
Conversely, among the one third of children 
with fever (>37.5°C) at screening, 28-day mortal-
ity with a transfusion volume of 30 ml per kilo-
gram was nearly twice as high as that with a 
transfusion volume of 20 ml per kilogram. In 
contrast, underlying disease (e.g., malaria and 
sickle cell disease) and physiological characteris-
tics (e.g., shock, oxygen saturation, heart rate, 
and lactate level) did not affect differences be-
tween the two groups, nor did differences in 
these characteristics or in C-reactive protein levels 
explain the differential effect according to the 
presence or absence of fever. Although 97.2% of 
the children had a history of fever, children who 
were febrile at screening remained febrile through 
8 hours, whereas nonfebrile children remained 
afebrile, which indicates that this measurement 
was not an isolated one.
One explanation for this finding could be the 
time course of intercurrent illness. Neither the 
length of illness nor referral from another health 
facility affected the response to the transfusion 
volume. However, in a post hoc analysis, effects 
of 30 ml per kilogram were strongest in children 
who received a transfusion within 2.5 hours 
after admission (Table S15 in the Supplementary 
Appendix). Alterations in the hemoglobin disso-
ciation curve with fever could alter the balance 
between risks and benefits from 30 ml as com-
pared with 20 ml per kilogram; however, the 
mechanism for harm with a higher transfusion 
volume in children with fever remains unclear. 
We are exploring several hypotheses related to 
infection, including altered iron metabolism. 
Further research is needed to understand how 
temperature might affect the risk–benefit ratio 
of transfusion volume. We observed few transfu-
sion-related adverse events nor cases of pulmo-
nary or cardiovascular overload with 30 ml per 
kilogram.
It is important that neither the use of whole 
blood (44% of units transfused) nor longer stor-
age age of (non–leukocyte-reduced) donor blood 
adversely affected 28-day or 180-day mortality. 
Thus, component preparation, recently introduced 
to blood-transfusion services in sub-Saharan 
Africa at substantial cost, does not appear to be 
essential for safe transfusion practice.
Strengths of the trial include broad eligibility 
criteria, which enhance generalizability, and high 
adherence to the randomized strategy and follow-
up (>95%). The enrollment of large subgroups of 
children with malaria and sickle cell disease 
should ensure relevance across Africa. An im-
portant limitation is that mortality was lower 
than anticipated, probably because of the consis-
tent standard of care provided by trial staff and 
the pausing of recruitment when blood was un-
available. However, the trial retained high power 
to identify effects on hospital readmissions 
(18% by day 180). The trial was open-label, by 
necessity; although adherence to thresholds for 
retransfusion was high, we cannot rule out the 
possibility that knowledge of group assignment 
influenced retransfusion for some children. Sub-
stantial uncertainty exists regarding costs of 
units of blood (which vary according to country), 
unit size and type, and hemoglobin testing and 
monitoring during the hospitalization. The eco-
nomic analysis does not capture longer-term 
mortality benefits, which could increase the 
cost-effectiveness (value for money) of 30 ml per 
kilogram in children without fever. Further imple-
mentation research is required to estimate cost 
savings from providing whole blood rather than 
packed or settled cells and to evaluate practical 
approaches to giving 30 ml per kilogram to chil-
dren without fever and 20 ml per kilogram to 
children with fever in real-world settings.
In conclusion, overall mortality did not differ 
between the two transfusion strategies. Among 
afebrile children, a transfusion volume of 30 ml 
of whole-blood equivalent per kilogram resulted in 
lower mortality and lower rates of re-transfusion 
than current recommendations of 20 ml per kilo-
gram. However, higher transfusion volume was 
associated with higher mortality among febrile 
children.
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